Assessing the effects of HPV vaccination in women in China
A Multicenter Cohort Study Assessing the Efficacy and Adverse Effects of Different HPV Vaccination in Chinese Women
This study is testing how well HPV vaccines work and if there are any side effects in women aged 9 to 45 in China.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 12000 (estimated) |
| Ages | 9 Years to 45 Years |
| Sex | Female |
| Sponsor | Fujian Maternity and Child Health Hospital Academic / other |
| Locations | 5 sites (Fuzhou, Fujian and 4 other locations) |
| Trial ID | NCT05932576 on ClinicalTrials.gov |
What this trial studies
This observational cohort study evaluates the efficacy and adverse effects of HPV vaccination among women aged 9 to 45 in six provinces across China. A total of 12,000 participants will be monitored for symptoms of adverse reactions and the effectiveness of the vaccine within 3 to 12 months after their last dose. The study involves telephone follow-ups and face-to-face evaluations, along with blood sample collection to measure antibody levels against HPV. The research aims to provide insights into the safety and effectiveness of various HPV vaccines available in the region.
Who should consider this trial
Good fit: Ideal candidates for this study are females aged 9 to 45 who have received their last dose of the HPV vaccine within the past 12 months.
Not a fit: Patients who are pregnant or lactating during HPV vaccination, or those who refuse follow-up and informed consent, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of HPV vaccine efficacy and safety, leading to improved vaccination strategies and public health outcomes.
How similar studies have performed: Other studies have shown positive outcomes regarding the efficacy and safety of HPV vaccines, indicating that this approach is supported by existing research.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: - Female, aged 9-45; Get the last dose of HPV vaccine within 12 months. Exclusion Criteria: - Pregnancy or lactation during HPV vaccination; Those who refuse follow-up and informed consent.
Where this trial is running
Fuzhou, Fujian and 4 other locations
- Fujian Maternity and Child Health Hospital — Fuzhou, Fujian, China (Recruiting)
- Fujian Provincial Center for Disease Control and Prevention — Fuzhou, Fujian, China (Recruiting)
- Maternal and Child Health Hospital of Shenzhen Province — Shenzhen, Guangdong, China (Recruiting)
- Maternal and Child Health Hospital of Hubei Province — Wuhan, Hubei, China (Recruiting)
- Xiangya Hospital, Central South University — Changsha, Hunan, China (Recruiting)
Study contacts
- Study coordinator: Dong Binhua
- Email: dbh18-jy@126.com
- Phone: 13599071900
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.